-
公开(公告)号:IE20120309A1
公开(公告)日:2013-05-08
申请号:IE20120309
申请日:2012-07-06
Applicant: HOWARD FOUNDATION HOLDINGS LTD
Inventor: NOLAN JOHN , BEATTY STEPHEN , LOUGHMAN JAMES , HOWARD ALAN , THURNHAM DAVID
Abstract: A composition comprising xanthophyll carotenoid mesozeaxanthin (MZ) for use as a dietary supplement or food additive for oral consumption for improving the visual performance of a human subject, in particular, a human subject not experiencing age-related macular degeneration (AMD). Visual performance may be assessed by measuring one or more of spatial contrast sensitivity function, (best corrected) visual acuity, glare disability, discomfort glare, ocular straylight, photostress recovery and S-cone sensitivity. The composition may also comprise lutein and/or zeaxanthin. A preferred combination is MZ/lutein/zeaxanthin in the ratio 10:10:2. Additional components may include one or more vitamins and/or minerals; a vegetable oil, fish oil and/or omega 3 fatty acid. The composition may be in the form of an egg obtained from a hen fed with a feed comprising MZ. A method of preparing the composition comprising the step of mixing an effective amount of MZ with an acceptable dietary diluent, excipient or carrier is also claimed.
-
公开(公告)号:GB2492881A
公开(公告)日:2013-01-16
申请号:GB201211920
申请日:2012-07-05
Applicant: HOWARD FOUNDATION HOLDINGS LTD
Inventor: NOLAN JOHN , BEATTY STEPHEN , LOUGHMAN JAMES , HOWARD ALAN , THURNHAM DAVID
IPC: A61K31/047 , A23L1/30 , A23L15/00 , A23L33/15 , A23L33/155
Abstract: A composition comprising xanthophyll carotenoid mesozeaxanthin (MZ) for use as a dietary supplement or food additive for oral consumption for improving the visual performance of a human subject, in particular, a human subject not experiencing age-related macular degeneration (AMD). Visual performance may be assessed by measuring one or more of spatial contrast sensitivity function, (best corrected) visual acuity, glare disability, discomfort glare, ocular straylight, photostress recovery and S-cone sensitivity. The composition may also comprise lutein and/or zeaxanthin. A preferred combination is MZ/lutein/zeaxanthin in the ratio 10:10:2. Additional components may include one or more vitamins and/or minerals; a vegetable oil, fish oil and/or omega 3 fatty acid. The composition may be in the form of an egg obtained from a hen fed with a feed comprising MZ. A method of preparing the composition comprising the step of mixing an effective amount of MZ with an acceptable dietary diluent, excipient or carrier is also claimed.
-
公开(公告)号:GB201207923D0
公开(公告)日:2012-06-20
申请号:GB201207923
申请日:2012-05-05
Applicant: HOWARD FOUNDATION HOLDINGS LTD
-
公开(公告)号:DE602005021632D1
公开(公告)日:2010-07-15
申请号:DE602005021632
申请日:2005-05-27
Applicant: HOWARD FOUNDATION HOLDINGS LTD
Inventor: HARRIS ROGER CHARLES , HOWARD ALAN NORMAN
-
公开(公告)号:CA2224217C
公开(公告)日:2010-04-13
申请号:CA2224217
申请日:1996-06-07
Applicant: HOWARD FOUNDATION
Inventor: HOWARD ALAN NORMAN , LANDRUM JOHN THOMAS , BONE RICHARD ANDREW
IPC: A61K31/047 , A23L33/00 , A23L33/15 , A23L33/155 , A61K31/01 , A61K31/015 , A61K31/045 , A61K31/07 , A61K31/12 , A61K31/22 , A61K31/23 , A61K31/355 , A61K31/375 , A61K33/04 , A61K33/24 , A61K33/30 , A61K33/32 , A61K33/34 , A61K36/185 , A61P27/00
Abstract: The carotenoids lutein and zeaxanthin are disclosed for pharmaceutical use in the treatment of advanced macular degeneration. High dosages are deployed to produce the high serum carotenoid levels needed to cause take-up by the macula.
-
公开(公告)号:PL196541B1
公开(公告)日:2008-01-31
申请号:PL35186900
申请日:2000-06-01
Applicant: HOWARD FOUNDATION
Inventor: HOWARD ALAN NORMAN , HARRIS ROGER CHARLES
IPC: A23L1/305 , A23L1/30 , A23L2/39 , A23L2/52 , A23L21/25 , A23L33/00 , A61K9/00 , A61K31/155 , A61K31/195 , A61K31/198 , A61K31/4168 , A61K45/06 , A61P3/02 , A61P21/00
-
公开(公告)号:CA2283778C
公开(公告)日:2007-08-21
申请号:CA2283778
申请日:1998-03-04
Applicant: HOWARD FOUNDATION
Inventor: BONE RICHARD ANDREW , ORTA CARLOS MANUEL , LANDRUM JOHN THOMAS , HUANG WENLUE
Abstract: A flicker photometer comprises generating means for generating two beams of light of different colours. Both beams are directed to a viewing means and a subject can vary the intensity of light from one beam relative to other. The colour of the light seen by the subject is caused to alternate by a shutter which is rotated about an axis by a motor, the shutter having a portion which extends non-perpendicularly relative to the axis to facilitate a compact construction of photometer. The performance of the photometer is improved by screens which scatter light before it reaches the subject. A first of the screens reflects light from one beam, whilst a second screen transmits light from the other. If light of wavelengths to which the eye is less sensitive is passed through the second screen, whilst light of a wavelength to which the eye is more sensitive passes through the first screen, the screens help to make it practicable for the generating means to use a single lamp to produce the light for both beams.
-
公开(公告)号:PT831797E
公开(公告)日:2007-06-01
申请号:PT96916256
申请日:1996-06-07
Applicant: HOWARD FOUNDATION
Inventor: HOWARD ALAN , LANDRUM JOHN , BONE RICHARD
-
公开(公告)号:DK0831797T3
公开(公告)日:2007-04-02
申请号:DK96916256
申请日:1996-06-07
Applicant: HOWARD FOUNDATION
Inventor: HOWARD ALAN NORMAN , LANDRUM JOHN THOMAS , BONE RICHARD ANDREW
IPC: A61K31/045 , A23L33/00 , A23L33/15 , A23L33/155 , A61K31/047 , A61K31/07 , A61K31/12 , A61K31/22 , A61K31/23 , A61K31/355 , A61K31/375 , A61K33/04 , A61K33/24 , A61K33/34 , A61P27/00
Abstract: The carotenoids lutein and zeaxanthin are used either separately or in combination to treat age-related macular degeneration (AMD). The carotenoids are administered in the form of a pharmaceutical preparation, e.g. a capsule or alternatively as a food e.g. a genetically engineered tomato producing enhanced levels of carotenoid. High dosages of lutein and zeaxanthin are needed to ensure high serum levels necessary for take up of the carotenoids by the macula.
-
公开(公告)号:AT355832T
公开(公告)日:2007-03-15
申请号:AT96916256
申请日:1996-06-07
Applicant: HOWARD FOUNDATION
Inventor: HOWARD ALAN NORMAN , LANDRUM JOHN THOMAS , BONE RICHARD ANDREW
IPC: A23L33/00 , A23L33/15 , A23L33/155 , A61K31/045 , A61K31/047 , A61K31/07 , A61K31/12 , A61K31/22 , A61K31/23 , A61K31/355 , A61K31/375 , A61K33/04 , A61K33/24 , A61K33/34 , A61P27/00
Abstract: The carotenoids lutein and zeaxanthin are used either separately or in combination to treat age-related macular degeneration (AMD). The carotenoids are administered in the form of a pharmaceutical preparation, e.g. a capsule or alternatively as a food e.g. a genetically engineered tomato producing enhanced levels of carotenoid. High dosages of lutein and zeaxanthin are needed to ensure high serum levels necessary for take up of the carotenoids by the macula.
-
-
-
-
-
-
-
-
-